MX2019002438A - Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus. - Google Patents
Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.Info
- Publication number
- MX2019002438A MX2019002438A MX2019002438A MX2019002438A MX2019002438A MX 2019002438 A MX2019002438 A MX 2019002438A MX 2019002438 A MX2019002438 A MX 2019002438A MX 2019002438 A MX2019002438 A MX 2019002438A MX 2019002438 A MX2019002438 A MX 2019002438A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds useful
- fused tricyclic
- pyridazinone compounds
- treat
- orthomyxovirus infections
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La invención proporciona compuestos de la Fórmula (I): (ver Fórmula) como se describe adicionalmente en la presente, así como composiciones farmacéuticas que comprenden dichos compuestos, y procedimientos para usar los compuestos y composiciones farmacéuticas para el tratamiento de ciertos trastornos víricos, incluyendo la influenza.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 | |
| PCT/IB2017/055137 WO2018042303A1 (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002438A true MX2019002438A (es) | 2019-07-08 |
| MX383124B MX383124B (es) | 2025-03-13 |
Family
ID=59923494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002438A MX383124B (es) | 2016-08-29 | 2017-08-25 | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus. |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11098051B2 (es) |
| EP (4) | EP3504214B1 (es) |
| JP (3) | JP7221861B2 (es) |
| CN (2) | CN109863151B (es) |
| AR (1) | AR109438A1 (es) |
| CA (1) | CA3035302A1 (es) |
| DK (1) | DK4356969T3 (es) |
| ES (3) | ES2859510T3 (es) |
| FI (1) | FI4356969T3 (es) |
| HR (1) | HRP20250885T1 (es) |
| HU (1) | HUE072776T2 (es) |
| JO (1) | JOP20170169A1 (es) |
| LT (1) | LT4356969T (es) |
| MX (1) | MX383124B (es) |
| PL (3) | PL4356969T3 (es) |
| PT (3) | PT4356969T (es) |
| SI (3) | SI4356969T1 (es) |
| TW (3) | TWI869757B (es) |
| UY (1) | UY37378A (es) |
| WO (1) | WO2018042303A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015038655A1 (en) * | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| CA3008607A1 (en) | 2015-12-15 | 2017-06-22 | Shionogi & Co., Ltd. | A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug |
| EP3426656B1 (en) | 2016-03-08 | 2021-05-12 | Novartis AG | Tricyclic compounds useful to treat orthomyxovirus infections |
| UA125218C2 (uk) | 2016-08-10 | 2022-02-02 | Сіоногі Енд Ко., Лтд. | Фармацевтичні композиції, що містять заміщені поліциклічні піридонові похідні та їх проліки |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| CN111848616B (zh) | 2018-01-17 | 2021-11-23 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及其用于制备抗流感病毒药物的用途 |
| US11629149B2 (en) * | 2018-02-28 | 2023-04-18 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
| CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
| CA3115792A1 (en) * | 2018-10-10 | 2020-04-16 | Janssen Biopharma, Inc. | Macrocyclic flu endonuclease inhibitors |
| CN115135646B (zh) * | 2019-12-23 | 2024-05-17 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
| WO2024228401A1 (ja) * | 2023-05-02 | 2024-11-07 | 国立大学法人 大分大学 | 新型コロナウイルス感染症の処置または予防用医薬としての置換三環式複素環化合物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2225112A (en) | 1938-07-09 | 1940-12-17 | Wright Aeronautical Corp | Air cleaner |
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| EP2181985B1 (en) | 2001-08-10 | 2011-10-26 | Shionogi & Co., Ltd. | Antiviral Agent |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| EP1725554A1 (en) | 2004-03-09 | 2006-11-29 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
| FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| NZ591728A (en) | 2008-10-31 | 2012-12-21 | Shionogi & Co | Cephalosporin having catechol group |
| WO2010110231A1 (ja) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された３－ヒドロキシ－４－ピリドン誘導体 |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| JP5737691B2 (ja) | 2009-06-15 | 2015-06-17 | 塩野義製薬株式会社 | 置換された多環性カルバモイルピリドン誘導体 |
| MX2012007273A (es) | 2009-12-23 | 2012-12-17 | Elan Pharm Inc | Pteridinonas como inhibidores de la quinasa tipo polo. |
| TW201201813A (en) | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| SI2620436T1 (en) * | 2010-09-24 | 2018-08-31 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| KR20140090197A (ko) | 2011-10-12 | 2014-07-16 | 시오노기세야쿠 가부시키가이샤 | 인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체 |
| EP2889287B1 (en) | 2012-09-20 | 2016-08-31 | Celltrion, Inc. | Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same |
| SG11201503946UA (en) | 2013-01-08 | 2015-09-29 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| HK1225716A1 (zh) | 2013-08-21 | 2017-09-15 | Alios Biopharma, Inc. | 抗病毒化合物 |
| EP3043806A4 (en) | 2013-09-11 | 2017-05-17 | University Of Southern California | A composition of stem cells having highly expressed fas ligand |
| WO2015038655A1 (en) | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| ES2724581T3 (es) | 2013-09-12 | 2019-09-12 | Janssen Biopharma Inc | Compuestos de piridazinona y usos de los mismos |
| JP2017521424A (ja) | 2014-07-07 | 2017-08-03 | ザヴィラ ファーマシューティカルズ ゲーエムベーハー | ウイルス疾患の治療、改善又は予防におけるジヒドロピリドピラジン−１，８−ジオン及びそれらの使用 |
| AU2016229147C1 (en) | 2015-03-11 | 2021-03-25 | Janssen Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| EP3426656B1 (en) | 2016-03-08 | 2021-05-12 | Novartis AG | Tricyclic compounds useful to treat orthomyxovirus infections |
| WO2017156407A1 (en) | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
| CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| UA125218C2 (uk) | 2016-08-10 | 2022-02-02 | Сіоногі Енд Ко., Лтд. | Фармацевтичні композиції, що містять заміщені поліциклічні піридонові похідні та їх проліки |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
| CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| CN111848616B (zh) | 2018-01-17 | 2021-11-23 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及其用于制备抗流感病毒药物的用途 |
| JP7200005B2 (ja) | 2018-02-28 | 2023-01-06 | 日本たばこ産業株式会社 | 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途 |
| JP7282546B2 (ja) | 2018-02-28 | 2023-05-29 | 日本たばこ産業株式会社 | ４－メチルジヒドロピリミジノン化合物及びその医薬用途 |
| PE20211456A1 (es) | 2018-02-28 | 2021-08-05 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |
| US11629149B2 (en) | 2018-02-28 | 2023-04-18 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
-
2016
- 2016-08-29 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
-
2017
- 2017-08-25 SI SI201731620T patent/SI4356969T1/sl unknown
- 2017-08-25 MX MX2019002438A patent/MX383124B/es unknown
- 2017-08-25 PL PL23217305.4T patent/PL4356969T3/pl unknown
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 FI FIEP23217305.4T patent/FI4356969T3/fi active
- 2017-08-25 PT PT232173054T patent/PT4356969T/pt unknown
- 2017-08-25 EP EP23217305.4A patent/EP4356969B1/en active Active
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 CN CN202110956692.7A patent/CN113683614B/zh active Active
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en not_active Ceased
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 ES ES20210329T patent/ES2974494T3/es active Active
- 2017-08-25 SI SI201731493T patent/SI3848372T1/sl unknown
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/pl unknown
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 DK DK23217305.4T patent/DK4356969T3/da active
- 2017-08-25 EP EP25187556.3A patent/EP4640279A3/en active Pending
- 2017-08-25 HU HUE23217305A patent/HUE072776T2/hu unknown
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 HR HRP20250885TT patent/HRP20250885T1/hr unknown
- 2017-08-25 ES ES23217305T patent/ES3042460T3/es active Active
- 2017-08-25 LT LTEP23217305.4T patent/LT4356969T/lt unknown
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-28 TW TW112101158A patent/TWI869757B/zh active
- 2017-08-28 TW TW113134345A patent/TW202517646A/zh unknown
- 2017-08-28 UY UY0001037378A patent/UY37378A/es active IP Right Grant
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es active IP Right Grant
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja not_active Withdrawn
-
2024
- 2024-06-13 US US18/743,020 patent/US20250011334A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009843A patent/JP2025081322A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002438A (es) | Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus. | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| PE20151594A1 (es) | Inhibidores de indolamina 2-3 dioxigenasa | |
| CL2018000198A1 (es) | Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr | |
| CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
| UY37128A (es) | Compuestos tetracíclicos de piridona como antivirales | |
| EA201690372A1 (ru) | Азапиридоновые соединения и их применение | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EA201790266A1 (ru) | Индолы для применения при инфекции, вызванной вирусом гриппа | |
| EA201790571A1 (ru) | Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа | |
| MX2018011785A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue. | |
| CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| PE20170440A1 (es) | Derivados de isoindolina | |
| MX2017011655A (es) | Compuestos de aza-piridona y usos de estos. | |
| CL2017000152A1 (es) | Derivados de isoindolinona | |
| MX369857B (es) | Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6). | |
| CL2017000151A1 (es) | Derivados de piridona | |
| SA520420046B1 (ar) | مركبات بيريدازينون ثلاثية الحلقة مندمجة وعقاقير أولية منها مفيدة لعلاج الإصابات الفيروسة المخاطية القويمة | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |